Official Website: Halia Therapeutics
source confidence: Medium status: Useful updated 2026-08-11
Summary
Halia Therapeutics' official genetic-resilience marketing homepage describes NEK7/HT-6184 clinical programs for MDS, obesity (semaglutide combination), and Alzheimer's (HT-4253), plus the GENMOR discovery platform and resilience-first drug-development framing.
Useful Claims
- Halia Therapeutics is a Lehi, Utah clinical-stage biopharmaceutical company — not stated on this genetic-resilience homepage capture.
- Ofirnoflast (HT-6184) is described as a first-in-class oral allosteric NEK7 inhibitor targeting NLRP3 inflammasome activation — not named on this capture; NEK7/HT-6184 linkage appears in the clinical-programs section.
- An ASH 2025 efficacy result reported elsewhere is absent from this homepage capture and should not be relied on without the conference disclosure.
- The Phase 2a trial NCT07052006 was listed as active, not recruiting, with enrollment of 37 (actual) and a 2026 completion date — not present in this capture.
- The disclosed pipeline includes an HT-6184 + semaglutide program for obesity/type 2 diabetes and a neuroinflammation candidate, HT-4253.
- The company's CEO/founder is David (Dave) Bearss.
Verbatim
"Resilience variants show immune system restoration via NEK7 inhibition, forming the foundation for HT-6184." — Home page, "Our Resilience-First Clinical Programs" (MDS)
"In preclinical models, HT-6184 enhances semaglutide efficacy while preserving lean mass." — Home page, "Our Resilience-First Clinical Programs" (Obesity)
"Greater weight loss was achieved when HT-6184 was combined with semaglutide vs. semaglutide alone in preclinical models" — Home page, statistics band
"Of Alzheimer's patients carry APOEA — Halia's HT-4253 targets protective variants that may delay or prevent onset" — Home page, statistics band
Reliability Notes
This record covers only the marketing homepage. Press releases and conference abstracts are leads, not neutral evidence; they reflect the sponsor's framing of early-stage data. Lehi headquarters, ofirnoflast (HT-6184) Phase 2a efficacy rates, trial NCT07052006 status, and CEO/founder attribution were not present in this capture. The ClinicalTrials.gov record is a reliable registry source for trial design, status, and enrollment. Financing details (amount raised, stage) are not established by these sources and need separate primary confirmation. Early efficacy signals do not predict success in larger confirmatory trials.